Re: Opinion: Here’s your guide to the upcoming biotechnology takeover wave
"They haven’t worked because we haven’t had a willing seller or the asset was too robustly competitive because it was a late-stage asset"
What is he saying here? That they'd prefer early stage assets? Seems so. Kind a suprprised at that, in only that the early stage assets are riskier, but I guess these guys aren't retail investors, and are far better equipped to evaulate risk, duh.
But it begs the question, where does EXEL sit within their minds in regard to this statement? Sounds to me that EXEL may be considered 'too robustly competitive because it was a late-stage asset".